# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wells Fargo analyst Derek Archila maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Equal-Weight and lowers the price t...
Apellis received $375 million in funding at close, with ability to access an additional $100 millionMajority of initial proceed...
Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target f...
HC Wainwright & Co. analyst Douglas Tsao reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $92 p...
UBS analyst Eliana Merle maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $89 to ...
Needham analyst Joseph Stringer reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $85 price target.
Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimat...
Mizuho analyst Graig Suvannavejh maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and lowers the price target ...